These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30045034)

  • 41. Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.
    Tomcsányi J; Nényei Z; Mátrai Z; Bózsik B
    JACC Clin Electrophysiol; 2016 Dec; 2(7):847-849. PubMed ID: 29759770
    [No Abstract]   [Full Text] [Related]  

  • 42. Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
    Giovanni B; Ibatici A; Sola S; Brunasso AMG; Massone C
    Am J Dermatopathol; 2020 Feb; 42(2):148-150. PubMed ID: 30839345
    [No Abstract]   [Full Text] [Related]  

  • 43. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
    Mato AR; Islam P; Daniel C; Strelec L; Kaye AH; Brooks S; Ganetsky A; Nasta S; Porter DL; Svoboda J; Nabhan C; Schuster SJ
    Blood; 2016 Feb; 127(8):1064-7. PubMed ID: 26702066
    [No Abstract]   [Full Text] [Related]  

  • 44. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Molica S
    Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].
    Léonard S; Hulin C; Anxionnat R; Grignon Y; Taillandier L; Vespignani H
    Rev Neurol (Paris); 2002 Nov; 158(11):1121-3. PubMed ID: 12451348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
    Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
    Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
    [No Abstract]   [Full Text] [Related]  

  • 48. Ibrutinib-Induced Neutrophilic Dermatosis.
    El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
    Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
    Hampel PJ; Ding W; Call TG; Rabe KG; Kenderian SS; Witzig TE; Muchtar E; Leis JF; Chanan-Khan AA; Koehler AB; Fonder AL; Schwager SM; Slager SL; Shanafelt TD; Kay NE; Parikh SA
    Leuk Lymphoma; 2019 Nov; 60(11):2712-2719. PubMed ID: 31014142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival adjusting for crossover: phase 3 study of ibrutinib
    Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
    Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
    [No Abstract]   [Full Text] [Related]  

  • 52. Ibrutinib-induced polyneuropathy: A case report.
    Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
    J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 54. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 55. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
    Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
    Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.
    Hadjadj J; Guffroy A; Delavaud C; Taieb G; Meyts I; Fresard A; Streichenberger N; L'Honneur AS; Rozenberg F; D'Aveni M; Aguilar C; Rosain J; Picard C; Mahlaoui N; Lecuit M; Hermine O; Lortholary O; Suarez F
    J Clin Immunol; 2019 Jan; 39(1):55-64. PubMed ID: 30552536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.